Trial
NCT02753595
Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Eisai Inc.
Collaborators
Halozyme Therapeutics
Condition
Metastatic Breast Cancer
Intervention
Eribulin mesylate
Why stopped
evolving standard of care and difficulties of enrolling participants
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-13